Brokerages Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) PT at $49.00

Pliant Therapeutics, Inc. (NASDAQ:PLRX) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are covering the company, MarketBeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock in the last year is $49.00.

PLRX has been the topic of a number of research analyst reports. Royal Bank of Canada boosted their price target on Pliant Therapeutics from $50.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 5th. HC Wainwright restated a “buy” rating and set a $48.00 price target on shares of Pliant Therapeutics in a research note on Wednesday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Pliant Therapeutics in a research note on Wednesday, April 10th.

Institutional Investors Weigh In On Pliant Therapeutics

A number of large investors have recently bought and sold shares of PLRX. China Universal Asset Management Co. Ltd. lifted its holdings in Pliant Therapeutics by 97.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,529 shares of the company’s stock valued at $27,000 after acquiring an additional 754 shares during the period. Acadian Asset Management LLC acquired a new position in Pliant Therapeutics in the first quarter valued at approximately $27,000. UBS Group AG lifted its holdings in Pliant Therapeutics by 18.4% in the second quarter. UBS Group AG now owns 3,537 shares of the company’s stock valued at $28,000 after acquiring an additional 550 shares during the period. Quest Partners LLC acquired a new position in Pliant Therapeutics in the fourth quarter valued at approximately $37,000. Finally, US Bancorp DE lifted its holdings in Pliant Therapeutics by 144.3% in the second quarter. US Bancorp DE now owns 2,150 shares of the company’s stock valued at $39,000 after acquiring an additional 1,270 shares during the period. Hedge funds and other institutional investors own 97.30% of the company’s stock.

Pliant Therapeutics Stock Performance

Shares of Pliant Therapeutics stock opened at $12.52 on Wednesday. The company has a market capitalization of $754.20 million, a PE ratio of -4.49 and a beta of 1.12. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.72 and a current ratio of 17.72. The company has a 50-day simple moving average of $15.15 and a two-hundred day simple moving average of $15.67. Pliant Therapeutics has a one year low of $12.00 and a one year high of $30.85.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.